CELLTRION INC

Celltrion steadies its 2026 gains amid peers’ swings, backed by a robust biosimilar pipeline, strong technical support, and attractive valuation in Korea’s biotech market.

Celltrion shares dip 1.67% as firm secures exclusive global license for next‑gen antibody KG‑013, shifting from biosimilars to innovative biologics and boosting investor confidence.

Celltrion stock rises 10.7% since last month, trading near its 200‑day SMA at KRW 196,700. Learn key market data, biotech focus, and how hybrid moves at Hyundai may influence the sector.

Celltrion’s 0.4% dip signals a deeper biotech slump, exposing liquidity and valuation risks amid a broader Korean market slide.